Healthcare provider profile · identity verified

Robert Quarcoo, D.O

Family Practice · FORT BRAGG, NC · NPI 1831402502

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Tramadol Hcl	Tramadol Hcl	250	97
Amlodipine Besylate	Amlodipine Besylate	191	114
Atorvastatin Calcium	Atorvastatin Calcium	179	100
Gabapentin	Gabapentin	157	65
Albuterol Sulfate Hfa	Albuterol Sulfate	133	53
Omeprazole	Omeprazole	123	65
Furosemide	Furosemide	104	43
Meloxicam	Meloxicam	98	48
Lisinopril	Lisinopril	96	46
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	93	41
Hydrochlorothiazide	Hydrochlorothiazide	90	49
Losartan Potassium	Losartan Potassium	81	42
Levothyroxine Sodium	Levothyroxine Sodium	78	34
Simvastatin	Simvastatin	67	39
Fluticasone Propionate	Fluticasone Propionate	64	36
Montelukast Sodium	Montelukast Sodium	64	30
Metoprolol Succinate	Metoprolol Succinate	60	33
Carvedilol	Carvedilol	55	33
Clonazepam	Clonazepam	54	19
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	52	29
Hydralazine Hcl	Hydralazine Hcl	50	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	30
Diclofenac Sodium	Diclofenac Sodium	47	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	28
Pravastatin Sodium	Pravastatin Sodium	47	27
Metformin Hcl	Metformin Hcl	45	31
Januvia	Sitagliptin Phosphate	39	15
Mirtazapine	Mirtazapine	39	26
Metformin Hcl Er	Metformin Hcl	38	20
Trazodone Hcl	Trazodone Hcl	38	22
Pantoprazole Sodium	Pantoprazole Sodium	37	24
Tamsulosin Hcl	Tamsulosin Hcl	37	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	19
Famotidine	Famotidine	35	23
Glipizide Er	Glipizide	35	18
Colchicine	Colchicine	34	18
Ozempic	Semaglutide	33	suppressed
Allopurinol	Allopurinol	31	22
Glipizide	Glipizide	31	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	30	17
Clobetasol Propionate	Clobetasol Propionate	28	19
Rosuvastatin Calcium	Rosuvastatin Calcium	28	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Linzess	Linaclotide	24	14
Eliquis	Apixaban	23	12
Acetaminophen-Codeine	Acetaminophen With Codeine	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Lovastatin	Lovastatin	22	13
Meclizine Hcl	Meclizine Hcl	22	suppressed
Pregabalin	Pregabalin	22	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	21	11
Potassium Chloride	Potassium Chloride	21	16
Azithromycin	Azithromycin	20	19
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Ammonium Lactate	Ammonium Lactate	18	11
Donepezil Hcl	Donepezil Hcl	17	11
Ibuprofen	Ibuprofen	17	12
Prednisone	Prednisone	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Fluconazole	Fluconazole	14	13
Levemir Flexpen	Insulin Detemir	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Baclofen	Baclofen	13	suppressed
Diazepam	Diazepam	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error